Regeneron Soars 4.24% on Groundbreaking Myeloma Drug Trial Data – Is This the Catalyst for a New Bull Run?

Summary
• Regeneron (REGN) surges 4.24% to $721.97, hitting an intraday high of $722.52
• New trial data reveals Lynozyfic eradicates residual multiple myeloma post-treatment
• Short interest rises 10.49%, but insider selling and bearish analyst ratings persist

Regeneron’s shares are surging on the back of a medical breakthrough in multiple myeloma treatment, with its dual-target antibody Lynozyfic showing unprecedented efficacy in eradicating residual cancer cells. The stock’s 4.24% rally has pushed it closer to its 52-week high of $790.98, despite a recent 7-day pullback. With short interest climbing and insider sentiment negative, the market is now weighing whether this trial success can reverse long-term underperformance or if regulatory risks and competition will cap gains.

Lynozyfic Trial Success Sparks Rally in Regeneron Shares
Regeneron’s 4.24% intraday surge is directly tied to preliminary data from a mid-stage trial of its dual-target antibody Lynozyfic, which eradicates residual multiple myeloma cells post-initial treatment. The drug, approved in July, binds to both CD3 (T cells) and BCMA (myeloma cells), achieving 100% negative residual disease in 18 participants. This breakthrough eliminates the need for bone marrow transplants in many patients, positioning Lynozyfic as a game-changer in myeloma care. The data, presented at the American Society of Hematology, has ignited investor optimism about Lynozyfic’s commercial potential, overshadowing recent short-term volatility.

Options Playbook: High-Leverage Calls for Aggressive Bulls
• 200-day MA: $598.90 (well below current price)
• RSI: 41.89 (oversold territory)
• MACD: 18.27 (bullish divergence from signal line at 29.23)
• Bollinger Bands: Price at $721.97, near lower band ($657.88) but trending upward

Regeneron’s technicals suggest a short-term breakout is underway, with the 52-week high of $790.98 as the next key target. The stock is trading above its 30D MA ($700.77) and 100D MA ($610.56), while RSI indicates oversold conditions. For aggressive bulls, the options chain offers two high-leverage calls:

• REGN20251219C720: Call option with 65.21% leverage, 18.14% IV, delta 0.5888, theta -1.9375, gamma 0.0179, turnover 4,005. This contract balances moderate delta with high leverage, ideal for a 5% upside scenario (projected price $757.07).
• REGN20251219C725: Call option with 100.53% leverage, 15.53% IV, delta 0.4954, theta -1.6545, gamma 0.0214, turnover 7,309. High liquidity and gamma make this a top pick for capitalizing on rapid price swings.

Aggressive bulls should prioritize REGN20251219C725 for its high leverage and liquidity, while REGN20251219C720 offers a safer entry. Both contracts benefit from the stock’s current momentum and the trial-driven narrative. If $722.52 holds, these options could deliver outsized returns as the stock tests $750.

Backtest Regeneron Stock Performance
Regeneron (REGN) experienced a notable intraday surge of approximately 4% on December 10, 2022. To evaluate the performance of REGN following this surge, we will analyze its stock price movement from December 10, 2022, to the present day.1. Initial Surge: The 4% intraday surge on December 10, 2022, was a significant event that likely influenced investor sentiment and market dynamics.2. Post-Surge Performance: It is essential to examine how REGN's stock price has performed in the subsequent months, especially considering any relevant news or events that may have impacted its trajectory.3. Recent News: REGN has recently announced the approval of Libtayo for advanced or recurrent cervical cancer, which could have positively influenced the stock. Additionally, the expanded use of Dupixent received a positive recommendation from the EMA, indicating potential growth for this drug.4. Market Reaction: The market's reaction to these announcements, as well as broader market trends and economic indicators, will have played a role in shaping REGN's performance since the surge.By analyzing the stock price changes from December 10, 2022, to the present day, we can assess the lasting impact of the 4% surge and evaluate REGN's overall performance in the context of recent news and market conditions.

Act Now: Regeneron’s Breakout Could Be Just the Beginning
Regeneron’s rally is fueled by a medical breakthrough with immediate commercial implications, but sustainability hinges on scaling production and navigating competition. The stock’s technicals and options activity suggest a short-term bullish bias, with key support at $692.50 and resistance at $722.52. Investors should monitor the 52-week high of $790.98 as a critical inflection point. Meanwhile, Johnson & Johnson (JNJ), the sector leader, is up 2.65%, signaling broader healthcare sector strength. For those seeking leverage, REGN20251219C725 offers a high-risk, high-reward play. Watch for a break above $722.52 to confirm the bullish case—and act decisively if it holds.